IP Library Granted Patent US 9,839,652
Granted Patent B2
US 9,839,652 · App. 15/088,863 · Granted Dec 12, 2017

Nanoparticle compositions and methods for treating or preventing tissue infections and diseases

Inventors: Bryon J. Tarbet (Highland, UT); William H. Niedermeyer (West Jordan, UT)
Assignee: ATTOSTAT, INC.
A61K33/38A61K9/0014A61K9/0019A61K9/0043A61K9/0073A61K9/06A61K9/08A61K9/107A61K9/1664A61K33/24A61K47/46A61L27/306A61L29/106A61L29/16A61L31/088A61L31/16A61K36/00A61L2400/06A61L2400/12A61L2420/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,839,652
App. No.
15/088,863
Granted
Dec 12, 2017
Kind
B2
Abstract

Stabilized multi-component antimicrobial compositions for treating tissue diseases, infections or conditions include a first and second set of differently sized and/or differently shaped metal nanoparticles, and a stabilizing agent. Compositions and treatment methods may be used for treating tissue diseases, infections or conditions caused by microbial infections, such as bacteria, viral, and/or fungal infections, or for preventing the infection of a wound, such as a cut, abrasion, ulcer, lesion, sore, and the like. The compositions and treatment methods disclosed herein may also be used as a prophylactic, and in some embodiments may be applied to otherwise healthy tissue in order to prevent or reduce the occurrence of a tissue disease, infection or condition.

Claims (41)

1. A nanoparticle composition for killing a microbe associated with a tissue infection or tissue disease and/or treating the tissue infection or tissue disease associated with the microbe, the composition comprising:

a first set of metal nanoparticles made by laser ablation so as to be nonionic and spherical-shaped with no external bond angles or edges and so as to have solid metal cores, a mean particle size in a range of about 1 nm to about 20 nm, and a narrow particle size distribution in which at least about 99% of the spherical-shaped metal nanoparticles are within ±3 nm of the mean particle size, wherein the first set of metal nanoparticles comprise ground state silver;

a second set of metal nanoparticles that differ from the first set of metal nanoparticles by at least one of comprising a different metal, made by a different process, having a different particle size and particle size distribution, or having a different shape, wherein the second set of metal nanoparticles comprise ground state gold; and

a stabilizing agent that prevents or reduces agglomeration of the metal nanoparticles as compared to a composition without the stabilizing agent.

2. The nanoparticle composition as in claim 1 , wherein the second set of nanoparticles potentiates the activity of the first set of nanoparticles in killing the microbe causing the tissue infection or tissue disease.

3. The nanoparticle composition as in claim 1 , wherein the second set of nanoparticles comprises coral-shaped metal nanoparticles made by laser ablation so that each is nonionic, has a non-uniform cross section, and has a globular structure with multiple non-linear strands joined together without right angles.

4. The nanoparticle composition as in claim 1 , wherein the composition is configured for treating a dermatological condition related to or caused by a virus and/or for killing the virus, and wherein the spherical nanoparticles have a mean particle size of about 8 nm or less.

5. The nanoparticle composition as in claim 1 , wherein the composition is configured for treating a dermatological condition related to or caused by bacteria and/or for killing the bacteria, and wherein the spherical nanoparticles have a mean particle size in a range of about 3 nm to about 14 nm.

6. The nanoparticle composition as in claim 1 , wherein the composition is configured for treating a dermatological condition related to or caused by a fungus and/or for killing the fungus, and wherein the spherical nanoparticles have a mean particle size in a range of about 9 nm to about 20 nm.

7. The nanoparticle composition as in claim 1 , wherein at least 99% of the spherical-shaped nanoparticles have a diameter within ±1 nm of the mean particle size.

8. The nanoparticle composition as in claim 1 , wherein the spherical-shaped nanoparticles have a ξ-potential of at least 30 mV (absolute value).

9. The nanoparticle composition as in claim 3 , wherein the coral-shaped metal nanoparticles have a particle size in a range of about 40 nm to about 100 nm.

10. The nanoparticle composition as in claim 3 , wherein the spherical-shaped nanoparticles are included at a concentration of between 1 and 15 ppm, and wherein the coral-shaped metal nanoparticles are included in a concentration of between 1 and 10 ppm.

11. The nanoparticle composition as in claim 1 , wherein the stabilizing agent is a natural-based polyphenol.

12. The nanoparticle composition as in claim 1 , wherein the stabilizing agent is provided by a plant-based extract selected from the group consisting of grape seed extract, arjuna bark, witch hazel, and combinations thereof.

13. The nanoparticle composition as in claim 1 , further comprising a solvent carrier comprised of one or more of water or alcohol.

14. A nanoparticle composition for treating a dermatological condition, comprising:

a set of spherical-shaped metal nanoparticles;

a set of coral-shaped metal nanoparticles made by laser ablation so that each is nonionic, has a non-uniform cross section, and has a globular structure with multiple non-linear strands joined together without right angles, the coral-shaped metal nanoparticles having a mean length in a range of about 15 nm to about 100 nm, at least 99% of the coral-shaped metal nanoparticles having a length within 30% of the mean length, and wherein the coral nanoparticles comprise ground state gold; and

a stabilizing agent that prevents or reduces agglomeration of the spherical-shaped and coral-shaped metal nanoparticles as compared to a composition without the stabilizing agent,

wherein the coral-shaped nanoparticles potentiate the activity of the spherical-shaped nanoparticles to enhance the effectiveness of the spherical-shaped nanoparticles.

15. The nanoparticle composition as in claim 14 , wherein the spherical-shaped metal nanoparticles are made by laser ablation.

16. The nanoparticle composition as in claim 15 , wherein the spherical-shaped metal nanoparticles are nonionic, have no external bond angles or edges, and have solid metal cores, a mean particle size in a range of about 1 nm to about 20 nm, and a narrow particle size distribution in which at least about 99% of the spherical-shaped metal nanoparticles are within ±3 nm of the mean particle size.

17. The nanoparticle composition as in claim 16 , wherein at least 99% of the spherical-shaped nanoparticles have a diameter within ±1 nm of the mean particle size.

18. The nanoparticle composition as in claim 14 , wherein the coral-shaped metal nanoparticles have a length in a range of about 40 nm to about 100 nm.

19. A nanoparticle composition for killing a microbe associated with a tissue infection or disease and/or treating the tissue infection or disease associated with the microbe, the composition comprising:

a carrier comprising one or more of water, alcohols, creams, gels, emulsions, solids, ketones, esters, citrus oils, essential oils, vegetable oils, plant oils, natural oils, triglycerides, ethers, organic solvents, methanol, ethanol, isopropyl alcohol, alcohols, glycols, glycerin, polyols, 1,3-propandiol, petroleum jelly, waxes, polymers, polymerizable materials, surfactants, stearic acid, coconut oil, olive oil, grape seed oil, vitamin E oil, emulsifying wax, saline solutions, benzyl alcohol, glycerin, naturally occurring phosphatides, lecithin, condensation products of an alkylene oxide with a fatty acid, polyoxyethylene stearate, condensation product of ethylene oxide with a long chain aliphatic alcohol, heptadecaethyleneoxycethanol, condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride, polyoxyethylene sorbitan monooleate, polysaccharides, polysaccharide compounds, dextran sulfate, glycoaminoglycans, glycosaminoglycan compounds, hyaluronic acid, dry powders, aerosols, low molecular weight hydrofluorocarbons or hydrocarbons, propylene glycol, polyethylene glycol, dextrose solutions, aqueous solutions containing electrolytes, mannitol, 1,3-butanediol, Ringer's solution, isotonic sodium chloride solution, synthetic mono- or diglycerides, fatty acids, oleic acid, cremaphor, and polymers; and

a first set of metal nanoparticles made by laser ablation so as to be nonionic and spherical with no external bond angles or edges and have solid metal cores, a ξ-potential of at least 30 mV (absolute value), a mean particle size in a range of about 1 nm to about 20 nm, and a narrow particle size distribution in which at least about 99% of the spherical metal nanoparticles are within ±3 nm of the mean particle size, wherein the first set of metal nanoparticles comprise ground state silver; and

a second set of metal nanoparticles that differ from the first set of metal nanoparticles by at least one of comprising a different metal, made by a different process, having a different particle size and particle size distribution, or having a different shape, wherein the second set of metal nanoparticles comprise ground state gold.

20. The nanoparticle composition as in claim 19 , wherein the nanoparticle composition is formulated to kill bacteria and wherein the mean particle size of the spherical metal nanoparticles is in a range of 3 nm to 14 nm.

21. The nanoparticle composition as in claim 20 , wherein the mean particle size is in a range of 5 nm to 13 nm.

22. The nanoparticle composition as in claim 20 , wherein the mean particle size is in a range of in a range of 7 nm to 12 nm.

23. The nanoparticle composition as in claim 20 , wherein the mean particle size is in a range of in a range of 8 nm to 10 nm.

24. The nanoparticle composition as in claim 19 , wherein the nanoparticle composition is formulated to kill viruses and wherein the mean particle size of the spherical metal nanoparticles is less than 8 nm.

25. The nanoparticle composition as in claim 24 , wherein the mean particle size is in a range of 1 nm to 7 nm.

26. The nanoparticle composition as in claim 24 , wherein the mean particle size is in a range of 2 nm to 6.5 nm.

27. The nanoparticle composition as in claim 24 , wherein the mean particle size is in a range of 3 nm to 6 nm.

28. The nanoparticle composition as in claim 19 , wherein the nanoparticle composition is formulated to kill fungi and wherein the mean particle size of the spherical metal nanoparticles is in a range of 9 nm to 20 nm.

29. The nanoparticle composition as in claim 28 , wherein the mean particle size is in a range of 10 nm to 18 nm.

30. The nanoparticle composition as in claim 28 , wherein the mean particle size is in a range of 11 nm to 16 nm.

31. The nanoparticle composition as in claim 28 , wherein the mean particle size is in a range of 12 nm to 15 nm.

Assignments (2)
CHANGE OF NAME Recorded Nov 23, 2021
From: ATTOSTAT, INC.
To: EVOQ NANO, INC.
Reel/Frame 058195/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2016
From: TARBET, BRYON J.; NIEDERMEYER, WILLIAM H.
To: ATTOSTAT, INC.
Reel/Frame 038175/0071 →
Continuity (3)
Provisional Application 62141692 · Apr 1, 2015
Provisional Application 62168094 · May 29, 2015
Related Publication 20160287631A1 · Oct 6, 2016